

APPLIED GENETIC TECHNOLOGIES CORP  
Form 8-K  
August 17, 2017

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): August 14, 2017**

**APPLIED GENETIC TECHNOLOGIES CORPORATION**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware  
(State or other jurisdiction  
of incorporation)**

**001-36370  
(Commission  
File Number)  
14193 NW 119<sup>th</sup> Terrace**

**59-3553710  
(IRS Employer  
Identification Number)**

**Suite 10**

**Alachua, Florida, 32165**

**(Address of principal executive offices) (Zip Code)**

**(386) 462-2204**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below).

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On August 14, 2017, Arnold L. Oronsky, Ph.D. notified us that he was resigning from our board of directors effective immediately. Dr. Oronsky's decision to resign from our board of directors was personal and was not the result of any disagreement with us on any matter related to our operations, policies or practices.

We thank Dr. Oronsky for his many years of service as a member of our board of directors and wish him the best in his future endeavors.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**APPLIED GENETIC TECHNOLOGIES**

**CORPORATION**

By: /s/ William A. Sullivan  
William A. Sullivan

Chief Financial Officer

Date: August 17, 2017